# MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct04834024/  
OnCo record `nct04834024` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.

## Summary

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT04834024 by Beijing Mabworks Biotech Co., Ltd., with 168 participants planned, started 2021-06-02 and due to reach its primary completion in 2025-03. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide and lenalinomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04834024
- Phase: 3
- Setting: A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab
- Sponsor: Beijing Mabworks Biotech Co., Ltd.
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT04834024: https://clinicaltrials.gov/study/NCT04834024

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- companies: [Beijing Mabworks Biotech](https://onco.cc/companies/beijing-mabworks-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct04834024.json